July 17th 2023
Shared insight from key opinion leaders in diffuse large B-cell lymphoma on the role of bispecific therapy in the relapsed/refractory space.
A brief review of what one can expect while managing a patient with relapsed/refractory diffuse large B-cell lymphoma on CAR T-cell therapy.
July 10th 2023
Moving into their last module, expert panelists consider how they might inform best selection and sequencing of therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
July 3rd 2023
A brief review of data behind lisocabtagene maraleucel and its role as CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
Shared insight on the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma, with a focus on axicabtagene ciloleucel.
June 26th 2023
Panelists review data behind the combination of tafasitamab and lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.
Focused discussion on specific patient or disease factors that aid in the selection of therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.
June 19th 2023
Key opinion leaders share a broad perspective on relapsed/refractory diffuse large B-cell lymphoma and the current treatment landscape.
Expert panelists open their discussion on diffuse large B-cell lymphoma by reflecting on diagnostic strategies and the frontline treatment armamentarium.
December 2nd 2022
Joanna M. Rhodes, MD, discusses evaluating the unmet needs of elderly patients in CLL.